Melissa McCarter
Psychiatric/Mental Health · Knoxville, TNNPI 1356305106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 681 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 681 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$966
- Otsuka America Pharmaceutical, Inc.$956
- AbbVie$844
- plus $6K from 27 others
What the payments were for
- Food & beverage$12,46499%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 78 | $1,756 |
| Vanda Pharmaceuticals Inc. | 43 | $1,074 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,030 |
| Lundbeck LLC | 63 | $966 |
| Otsuka America Pharmaceutical, Inc. | 58 | $956 |
| AbbVie | 51 | $844 |
| Axsome Therapeutics, Inc. | 49 | $806 |
| Teva Pharmaceuticals USA, Inc. | 47 | $794 |
| Alkermes, Inc. | 39 | $761 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $558 |
| Johnson & Johnson | 28 | $487 |
| Bausch Health US, LLC | 25 | $384 |
| Tris Pharma Inc | 20 | $345 |
| Sunovion Pharmaceuticals Inc. | 14 | $283 |
| Supernus Pharmaceuticals, Inc. | 16 | $243 |
| Corium, LLC | 10 | $229 |
| E.r. Squibb & Sons, L.L.C. | 12 | $188 |
| Almatica Pharma LLC | 7 | $128 |
| Gilead | 3 | $101 |
| Seagen Inc. | 1 | $100 |
| Eisai Inc. | 6 | $88 |
| Neos Therapeutics, LP | 5 | $83 |
| AstraZeneca | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Indivior Inc. | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $20 |
| Merck | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
How this compares
$12,565 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $97,146 |
| Risperdal ConstaRisperidone Microspheres | 13 | $35,271 |
| VraylarCariprazine Hcl | 11 | $14,225 |
| BelsomraSuvorexant | 20 | $8,963 |
| Aripiprazole | 72 | $5,905 |
| Bupropion XlBupropion Hcl | 298 | $5,246 |
| CymbaltaDuloxetine Hcl | 11 | $3,033 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $2,992 |
| Prazosin Hcl | 65 | $2,293 |
| Buspirone Hcl | 154 | $1,931 |
| Hydroxyzine Hcl | 82 | $1,712 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 104 | $1,687 |
| Clonazepam | 139 | $1,652 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,601 |
| Atomoxetine Hcl | 13 | $1,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,756 | $97,14612 claims |
| Johnson & JohnsonRisperdal Consta | $487 | $35,27113 claims |
| AbbVieVraylar | $844 | $14,22511 claims |
| MerckBelsomra | $19 | $8,96320 claims |
| Almatica Pharma LLCSertraline Hcl | $128 | $713129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Knoxville
- Katherine SullivanKnoxville$17K
- Melissa SpearsKnoxville$12K
- Sarah LordKnoxville$10K
- Chenoa ShenandoahKnoxville$10K
- Sarah BannisterKnoxville$9K
- Brittani ArrowoodKnoxville$9K
- Lori HestandKnoxville$8K
- Lindsey WondoloskiKnoxville$8K
- Justin MynattKnoxville$8K
- Laura MelaroBolivar$682K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.